<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124358</url>
  </required_header>
  <id_info>
    <org_study_id>063005</org_study_id>
    <secondary_id>H97HA03795</secondary_id>
    <nct_id>NCT00124358</nct_id>
  </id_info>
  <brief_title>Buprenorphine and Integrated HIV Care Evaluation</brief_title>
  <official_title>An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The New York Academy of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Resources and Services Administration (HRSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>El Rio Santa Cruz Neighborhood Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Organization to Achieve Solutions in Substance Abuse (OASIS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CORE Center, Cook County Bureau of Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The New York Academy of Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility, cost and effectiveness of
      interventions designed to integrate buprenorphine treatment for opioid dependence into HIV
      primary care in ten HIV care centers in the U.S.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Programs that integrate medical care and drug treatment have shown great promise in improving
      health and substance use related outcomes. The overlap in the epidemics of HIV (with its
      complex medical needs) and drug abuse makes HIV-infected drug users a population likely to
      benefit from the integration of primary care and drug treatment. The Drug Addiction Treatment
      Act of 2000 and the approval of buprenorphine for the office-based treatment of opioid
      addiction provide a new opportunity to integrate addiction treatment and medical care for
      people with HIV. Research has demonstrated the effectiveness of buprenorphine in reducing
      illicit drug use among opioid dependent people. However, little is known about implementing
      such programs in HIV care settings, their cost, what effect they have on the health outcomes
      and substance use behavior of PLWH/A, or their broader impact on providers, institutions, and
      local systems.

      Through this study, approximately 1,350 HIV-infected individuals who meet criteria for opioid
      dependence will be selected by eleven model demonstration projects located in ten HIV care
      centers across the U.S. Information on patients’ drug use, HIV health status, service
      utilization, quality of life, and satisfaction with services as well as information about
      providers’ practices and attitudes towards treating drug dependent patients will be collected
      through face-to-face interviews, audio computer-assisted self-interviewing, written surveys,
      and chart abstractions. These data will be used to help replicate effective programs that
      integrated HIV care and drug treatment and to improve the care of HIV-infected opioid
      dependent individuals.

      Comparisons: All eleven programs will compare a group of patients who receive integrated
      buprenorphine treatment and HIV care to a group of patients who receive an alternate
      intervention. However, the program designs and comparison group interventions vary across the
      sites and are locally determined. Some sites will implement randomized control designs, while
      others will use observational methods.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Substance use outcomes at 1, 3 and 6 months measured by self-report</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine toxicology results at 1, 3, 6, and 12 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention in and adherence to HIV care at 1, 3, 6, and 12 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life at 1, 3, 6, 9, and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-related health outcomes at 1, 3, 6, 9, and 12 months</measure>
  </secondary_outcome>
  <enrollment>1350</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Integrated HIV care and office-based opioid dependence treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected

          -  Clinical diagnosis of opioid dependence

          -  Fluent in English or Spanish

          -  18 years or older

        Exclusion Criteria:

          -  Liver function tests (transaminase only) at five times or higher than normal level;

          -  Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria
             for benzodiazepine abuse or dependence within the past 6 months;

          -  DSM-IV criteria for alcohol dependence within the past 6 months;

          -  Actively suicidal;

          -  Psychiatric impairment that impedes ability to consent (dementia, delusional, actively
             psychotic);

          -  Methadone dose exceeding levels allowing for safe transition to buprenorphine;

          -  Pregnant women and women actively trying to become pregnant;

          -  Clinical judgment of local site principal investigator that patient is inappropriate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Finkelstein, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Academy of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Fiellin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Finkelstein, ScD</last_name>
    <phone>212.822.7266</phone>
    <email>rfinkelstein@nyam.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James E Egan, MPH</last_name>
    <phone>212.822.7347</phone>
    <email>jegan@nyam.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>El Rio Santa Cruz Neighborhood Health Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Thomas, ACSW</last_name>
      <phone>520-629-2888</phone>
      <email>jefft@elrio.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Carmichael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Organization to Achieve Solutions in Substance Abuse</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laphyne Barrett, MA</last_name>
      <phone>510-834-5442</phone>
    </contact>
    <investigator>
      <last_name>Diana Sylvestre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Thawley</last_name>
      <phone>415-476-9296</phone>
      <phone_ext>311</phone_ext>
      <email>rthawley@php.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Paula Lum, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline Tulsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine AIDS Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Declan Barry, PhD</last_name>
      <phone>203-781-4650</phone>
      <phone_ext>250</phone_ext>
      <email>declan.barry@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Frederick Altice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lynn Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Thompson, RN, BSN</last_name>
      <phone>305-243-3838</phone>
      <email>lthomps@gate.net</email>
    </contact>
    <investigator>
      <last_name>Margaret Fischl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Metsch, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jo Tozzi</last_name>
      <phone>312-572-4818</phone>
      <email>mtozzi@corecenter.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Watts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Barker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Lucas, MD, PhD</last_name>
      <phone>410-614-0560</phone>
      <email>glucas@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Greg Lucas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yngveld Olsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Ruby, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Hsu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeanne Keruly, CRNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Moore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galit Sacajiu, MD</last_name>
      <email>gsacajiu@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Chinazo Cunningham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy Sohler, PhD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Pedersen, MPA</last_name>
      <phone>503-494-6770</phone>
    </contact>
    <investigator>
      <last_name>P. Todd Korthuis, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis McCarty, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Loewenthal, MSW</last_name>
      <phone>401-793-4824</phone>
      <email>hloewenthal@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Flanigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Friedman, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2005</study_first_posted>
  <last_update_submitted>March 23, 2007</last_update_submitted>
  <last_update_submitted_qc>March 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2007</last_update_posted>
  <keyword>Drug Abuse</keyword>
  <keyword>Drug Addiction</keyword>
  <keyword>Drug Dependence</keyword>
  <keyword>Drug Use Disorders</keyword>
  <keyword>Drug Use Disorder</keyword>
  <keyword>Substance Abuse</keyword>
  <keyword>Substance Use Disorder</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Opiate Addiction</keyword>
  <keyword>Substance-related disorders</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

